Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12507607 | 0.85 | POLB (0.48) | POLBCYP2C19L3MBTL1SMN1; SMN2PIK3CD | |
| SCHEMBL10025301 | 0.81 | CYP2C19 (0.39) | POLBCYP2C19L3MBTL1SMN1; SMN2PIK3CD | |
| SCHEMBL8278732 | 0.78 | POLB (0.46) | POLBCYP2C19L3MBTL1SMN1; SMN2PIK3CD | |
| SCHEMBL12416120 | 0.77 | CHRM2 (0.41) | — | |
| SCHEMBL14283018 | 0.76 | PIK3CD (0.45) | POLBCYP2C19PIK3CDPIK3CAPIK3CB | |
| SCHEMBL10304516 | 0.76 | PIK3CD (0.45) | POLBCYP2C19PIK3CDPIK3CAPIK3CB | |
| SCHEMBL12507593 | 0.76 | L3MBTL1 (0.40) | POLBCYP2C19L3MBTL1SMN1; SMN2RXFP1 | |
| SCHEMBL12416119 | 0.76 | ALDH1A1 (0.41) | POLBL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL10304592 | 0.75 | PIK3CD (0.47) | POLBCYP2C19L3MBTL1PIK3CDPIK3CA | |
| SCHEMBL14283026 | 0.75 | PIK3CD (0.47) | POLBCYP2C19L3MBTL1PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130177531-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-11 | — | — | US | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | POLB 4056/4885CYP2C19 1185/4885L3MBTL1 2511/4885 |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | POLB 4056/4885CYP2C19 1185/4885L3MBTL1 2511/4885 |
| US-20130177531-A1 | Inhibitors of Serine Proteases | PRSS1, SERPINB1, PRSS3 | POLB 4056/4885CYP2C19 1185/4885L3MBTL1 2511/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | POLB 4042/4885CYP2C19 1215/4885L3MBTL1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.